Abstract 44P
Background
Management of Her-2 negative breast cancer is evolving. Literature on response and outcomes to neoadjuvant chemotherapy (NACT) is limited from the Indian subcontinent. In this study, we evaluated the pathological complete response(pCR) rates to NACT, and outcomes in Her2-negative breast cancers, which includes TNBC and hormone receptor-positive (HR+) cohorts.
Methods
Her2-negative breast cancer patients who received neoadjuvant chemotherapy and then underwent surgery between January 2017 and December 2021 at a tertiary cancer hospital in India were included. Pathological response to chemotherapy, and outcomes were noted by retrospective electronic medical record review. pCR was defined as complete disappearance of all invasive carcinoma cells in the breast and axillary lymph nodes (ypT0/ypN0).
Results
Of the 1760 Her-2 negative breast cancers who were registered at our institute in the above time period, 232 patients received NACT, and 172 patients who completed NACT and then underwent surgery were included in the analysis. The median age of presentation was 50 years (Range 31-74 years). The median age was 46 years in the TNBC cohort, and 55 years in HR+ cohort. Majority of the patients received anthracycline/taxane based chemotherapy, and 94.1% (162/172) of the patients received all planned cycles of chemotherapy before surgery. Overall pathological complete response (pCR) was seen in 27.3% of patients (47/175). pCR rates were significantly higher in the TNBC cohort compared to HR+ cohort (38.2% vs 15.6 %, P - 0.001). TNBC variant and higher histologic grade (Grade III) were associated with significantly higher pCR rates. At a median follow-up of 30.8 months, 23.2% of patients (40/172) developed relapse (26.9% in TNBC, 19.2 % in HR+). Patients who achieved pCR had significantly lower chances of recurrence compared to those with non-pCR to chemotherapy (12.7% vs 27.2%, P- 0.045).
Conclusions
Triple-negative breast cancer subtype and higher histologic grade are associated with significantly higher pathological complete response to NACT. Achieving complete pathological response is associated with lower risk of breast cancer recurrence, and it is an important surrogate marker for recurrence-free and overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract